Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Stoekenbroek, R."'
Pooled Safety and Efficacy of Inclisiran in Patients With Statin Intolerance (ORION-10 and ORION-11)
Autor:
McQuillan, B., Wright, R., Kallend, D., Raal, F., Stoekenbroek, R., Koenig, W., Leiter, L., Landmesser, U., Schwartz, G., Wijngaard, P., Kastelein, J., Ray, K.
Publikováno v:
In Heart, Lung and Circulation July 2023 32 Supplement 3:S299-S299
Autor:
Psaltis, P., Wright, S., Raal, F., Kallend, D., Stoekenbroek, R., Koenig, W., Leiter, L., Landmesser, U., Schwartz, G., Wijngaard, P., Kastelein, J., Ray, K.
Publikováno v:
In Heart, Lung and Circulation July 2023 32 Supplement 3:S291-S291
Autor:
Ooi, E., Ray, K., Kallend, D., Raal, F., Stoekenbroek, R., Koenig, W., Leiter, L., Landmesser, U., Schwartz, G., Wijngaard, P., Kastelein, J., Wright, R.
Publikováno v:
In Heart, Lung and Circulation July 2023 32 Supplement 3:S270-S271
Autor:
Landmesser, U, Haghikia, A, Leiter, LA, Wright, RS, Kallend, D, Wijngaard, P, Stoekenbroek, R, Kastelein, JJP, Ray, KK
INTRODUCTION: siRNA-based targeting of PCSK9 represents a novel therapeutic approach that may provide a convenient, infrequent and safe dosing schedule to robustly lower LDL-C. Given the long duration of action, however, establishing safety in partic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1032::a1871284f9cf60ccf2ac215121c1b7bd
http://hdl.handle.net/10044/1/78216
http://hdl.handle.net/10044/1/78216
Publikováno v:
Clinical Cardiogenetics ISBN: 9783030454562
Clinical Cardiogenetics ISBN: 9783319442020
Clinical Cardiogenetics: Third Edition, 387-411
STARTPAGE=387;ENDPAGE=411;TITLE=Clinical Cardiogenetics: Third Edition
Clinical Cardiogenetics ISBN: 9783319442020
Clinical Cardiogenetics: Third Edition, 387-411
STARTPAGE=387;ENDPAGE=411;TITLE=Clinical Cardiogenetics: Third Edition
Disorders of lipoprotein metabolism are major contributors to cardiovascular disease (CVD). Dyslipidemia refers to elevated LDL-C levels, triglycerides, or remnant cholesterol, and decreased HDL-C. Most cases of CVD are multifactorial and/or polygeni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fa8b97605f66bde79719e9835f5db8c
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85150114497&origin=inward
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85150114497&origin=inward
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Handbook of experimental pharmacology, 224, 631-648. Springer Heidelberg
A wealth of evidence indicates that plasma levels of high-density lipoprotein cholesterol (HDL-C) are inversely related to the risk of cardiovascular disease (CVD). Consequently, HDL-C has been considered a target for therapy in order to reduce the r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=narcis______::45dad08e2ab22808ca2ef800439f45e7
https://pure.amc.nl/en/publications/apoai-mimetics(77f81fcd-5d43-4857-b551-b35b27051be9).html
https://pure.amc.nl/en/publications/apoai-mimetics(77f81fcd-5d43-4857-b551-b35b27051be9).html
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Kallend, D., Collins, M., Kastelein, J., Landmesser, U., Leiter, L., Ray, K., Robson, R., Stoekenbroek, R., Wright, R.S., Wijngaard, P.
Publikováno v:
In Atherosclerosis August 2019 287:e38-e38
Publikováno v:
In Atherosclerosis August 2019 287:e7-e7